Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine ...
Nasal vaccines offer convenience and another option for those wary of needles, but traditional vaccines are best for young ...
The cb1 vaccine platform demonstrates a single, intranasally administered vaccine can confer wide-ranging immunity that may ...
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early phase clinical trial that found an ...
Intranasal flu vaccines may be able to provide long-lasting protection against pandemic flu strains, according to a new study from immunologists at Columbia University Medical Center (CUMC). The ...
In a phase I trial, an intranasal adjuvanted recombinant influenza vaccine appeared to result in response to a range of H5N1 clades. The adjuvanted vaccine elicited seroconversion against clade 2 ...
AptarGroup has recently declared a quarterly cash dividend of US$0.48 per share, payable on February 25, 2026, to ...
In hopes of staying ahead of an evolving SARS-Cov-2 virus, scientists turn to intranasal vaccines to trigger mucosal immunity. Issue: Despite huge scientific gains in developing the original group of ...
Last week, AstraZeneca released a vaccine in the U.S. with one very unique quality: You can give it yourself, at home. FluMist Home is an influenza vaccine that’s administered via nasal spray, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results